



0300

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Warren, et al.

Examiner: NYA

Serial No.: 09/813,463

Group Art Unit: 1653

Filed: March 20, 2001

Docket: 098810/0278740

For: **PEPTIDE SPECIFICITY OF ANTI-MYELIN BASIC PROTEIN AND THE
ADMINISTRATION OF MYELIN BASIC PROTEIN PEPTIDES TO MULTIPLE
SCLEROSIS PATIENTS**

TRANSMITTAL

U.S. Patent and Trademark Office
Box Sequence Listing, P.O. Box 2327
Arlington, VA 22202

Sir:


Transmitted herewith in the above-identified application are the following documents:

1. Response to Notice to Comply;
2. Sequence Listing in computer readable format and paper copy;
3. Statement Under 37 CFR § 1.821(f) and (g);
4. Copy of Notice to Comply; and
5. Postcard.

Respectfully submitted,

PILLSBURY WINTHROP LLP

Date: 3-14-02


Robert M. Bedgood
Reg. No. 43,488

CERTIFICATE OF MAILING BY EXPRESS MAIL

Under 37 C.F.R. § 1.8

I hereby certify under 37 C.F.R. § 1.8 that this Response and corresponding transmittal documents are being deposited with the United States Postal Service to Addressee with sufficient postage on the date indicated below and is addressed to United States Patent and Trademark Office, Box Sequence Listing, P.O. Box 2327, Arlington, VA 22202

Dated: 3/14/02


SUZANNE L. SIMPSON



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/813,463	01/11/2002	Kenneth G. Warren	098810/0278740

Jane K. Babin
Pillsbury Winthrop LLP
50 Fremont Street
San Francisco, CA 94105



CONFIRMATION NO. 8427

FORMALITIES LETTER



OC000000007473545

Date Mailed: 02/14/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Warren, et al.

Examiner: NYA

Serial No.: 09/813,463

Group Art Unit: 1653

Filed: March 20, 2001

Docket: 098810/0278740

For: **PEPTIDE SPECIFICITY OF ANTI-MYELIN BASIC PROTEIN AND THE
ADMINISTRATION OF MYELIN BASIC PROTEIN PEPTIDES TO MULTIPLE
SCLEROSIS PATIENTS**

RESPONSE TO NOTICE TO COMPLY

U.S. Patent and Trademark Office
Box Sequence Listing, P.O. Box 2327
Arlington, VA 22202

Sir:

Responsive to the communication mailed February 14, 2002, Applicants submit herewith a paper copy and a computer readable form (diskette) of the sequence listing as required under 37 C.F.R. §1.824 (a). The sequence listing is provided in ASCII text on the accompanying diskette. A copy of the notice to comply is attached to this response.


The paper copy and computer readable forms of the sequence listing are identical and do not add new matter. A statement under 37 C.F.R. §1.821 (f) and (g) to that effect is provided. Accordingly, please amend the specification by entering the enclosed sequence listing.

Respectfully submitted,

PILLSBURY WINTHROP LLP

Date: _____

3-14-02


Robert M. Bedgood
Reg. No. 43,488

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Warren, et al.

Serial No.: 09/813,463

Filed: March 20, 2001

For: **PEPTIDE SPECIFICITY OF ANTI-MYELIN BASIC PROTEIN AND THE
ADMINISTRATION OF MYELIN BASIC PROTEIN PEPTIDES TO MULTIPLE
SCLEROSIS PATIENTS**

Examiner: NYA

Group Art Unit: 1653

Docket: 098810/027 8740



#13

STATEMENT UNDER 37 C.F.R. § 1.821 (f) and (g)

U.S. Patent and Trademark Office
Box Sequence Listing, P.O. Box 2327
Arlington, VA 22202

Sir:


The contents of the paper copy of the SEQUENCE LISTING and computer readable form submitted herewith are the same. The paper copy of the SEQUENCE LISTING and the computer readable form of the SEQUENCE LISTING do not add new matter.

Respectfully submitted,

PILLSBURY WINTHROP LLP

Date: _____

3-14-02


Robert M. Bedgood
Reg. No. 43,488

PILLSBURY WINTHROP LLP
50 Fremont Street
San Francisco, CA 94105
(858) 509-4065 Direct Dial
(415) 983-1200 Facsimile